Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Tianjin Pharmaceutical Da Ren Tang Group Current Ratio Related Terms
Tianjin Pharmaceutical Da Ren Tang Group Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group Current Ratio Chart
Tianjin Pharmaceutical Da Ren Tang Group Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin Pharmaceutical Da Ren Tang Group Current Ratio vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) has a Current Ratio of 1.38 as of Jun. 2026. This is 38% below median its historical median of 2.21. Over the past decade, Tianjin Pharmaceutical Da Ren Tang Group's Current Ratio has ranged from 1.38 to 2.81. According to the industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #682 out of 997 companies in the Drug Manufacturers industry, placing it in the top 68.4%.
Is Tianjin Pharmaceutical Da Ren Tang Group's Current Ratio too high?
Tianjin Pharmaceutical Da Ren Tang Group's current Current Ratio of 1.38 is 38% below median its 10-year median of 2.21. Over the past 10 years, this metric has ranged from a low of 1.38 to a high of 2.81. The Drug Manufacturers industry median Current Ratio is 1.96. Tianjin Pharmaceutical Da Ren Tang Group's value of 1.38 is 29.6% below this industry median. Based on the distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #682 out of 997 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #682 out of 997 companies for Current Ratio. This places Tianjin Pharmaceutical Da Ren Tang Group in the lower half of its industry. The industry median Current Ratio is 1.96. Tianjin Pharmaceutical Da Ren Tang Group's value of 1.38 is 29.6% below this benchmark. Historically, Tianjin Pharmaceutical Da Ren Tang Group's own Current Ratio has ranged from 1.38 to 2.81 over the past decade. While the company's 10-year median is 2.21 vs. the industry median of 1.96, Tianjin Pharmaceutical Da Ren Tang Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.96, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin Pharmaceutical Da Ren Tang Group's current Current Ratio of 1.38 is 29.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin Pharmaceutical Da Ren Tang Group's current Current Ratio is 1.38, which is 38% below median its own 10-year median of 2.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.64, compared to a current price of $2.65 — trading 61.6% above its estimated fair value. The current Current Ratio is 1.38, which is 38% below median its 10-year median of 2.21 and 29.6% below the Drug Manufacturers industry median of 1.96. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14), the current Current Ratio is 1.38 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued.
The current stock price of $2.65 is trading 61.6% above its estimated GF Value™ of $1.64.
GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.
Key valuation signals for SGX:T14:
Current Ratio: 1.38 (38% below median its 10-year median of 2.21)
GF Value™: $1.64 vs. price of $2.65 (61.6% above fair value)
Industry Position: 29.6% below the Drug Manufacturers median (#682 of 997)
No single metric tells the full story. See the SGX:T14 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
66GF Score
Get the complete analysis for SGX:T14
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:T14 has been successfully added to your 
